Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 1;27(4):e319-e329.
doi: 10.4317/medoral.25253.

Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study

J-O Martins  1 , M-M Borges, C-E Malta, A-C Carlos, A-A Crispim, J-F Moura, I-J Fernandes-Lima, P-G Silva
Affiliations

Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study

J-O Martins et al. Med Oral Patol Oral Cir Bucal. .

Abstract

Background: This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM).

Material and methods: Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: However, specific conditions such as mucositis are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention). Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p<0.05).

Results: Among 19,000 total evaluations of 3,529 patients during 5.32±4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n=1,195). Chemotherapy duration (p<0.001), female sex (p=0.001), adjuvant intention (p=0.008) and the use of carboplatin (p=0.001), cisplatin (p=0.029), docetaxel (p<0.001) and bevacizumab (p=0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p=0.017), chemotherapy duration (p=0.018), BMI>30 (p=0.008), radiotherapy (p=0.037) and use of carboplatin (p=0.046) and cyclophosphamide (p=0.010) increased this prevalence.

Conclusions: Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors have no conflicts of interest.

References

    1. Rallis KS, Lai Yau TH, Sideris M. Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. Anticancer Res. 2021;41:1–7. - PubMed
    1. Chaveli-López B. Oral toxicity produced by chemotherapy: A systematic review. J Clin Exp Dent. 2014;6:81–90. - PMC - PubMed
    1. Gamper EM, Giesinger JM, Oberguggenberger A, Kemmler G, Wintner LM, Gattringer K. Taste alterations in breast and gynaecological cancer patients receiving chemotherapy: prevalence, course of severity, and quality of life correlates. Acta Oncol. 2012;51:490. - PubMed
    1. Selle F, Gligorov J, Soares DG, Lotz JP. High-dose chemotherapy as a strategy to overcome drug resistance in solid tumors. Bull Cancer. 2016;103:861–8. - PubMed
    1. Jones JA, Avritscher EB, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2020;14:505–15. - PubMed